Tafluprost

Class: Prostaglandin Analogs
Chemical Name: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid, 1-methylethyl ester
Molecular Formula: C₂₅H₃₄F₂O₅
CAS Number: 209860-87-7
Brands: Zioptan

Medically reviewed by Drugs.com on Nov 2, 2020. Written by ASHP.

Introduction

Ocular hypotensive agent; fluorinated analog of prostaglandin F_2α (PGF_2α).

Uses for Tafluprost

Ocular Hypertension and Glaucoma

Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Preservative free; may be useful in patients who are allergic or have adverse events related to preservative-containing ocular hypotensives, have sensitive or dry eyes, or do not adequately respond to or cannot tolerate other therapies (e.g., topical prostaglandin analogs).

As effective as timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Not as effective as latanoprost 0.005% and may be less effective than travoprost 0.004%.

Addition of tafluprost 0.0015% to timolol 0.5% therapy may result in additional reduction in IOP.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.

A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activity, once-daily administration, and low frequency of systemic adverse effects; however, ocular adverse effects can occur.

Goal is to maintain an IOP at which visual field loss is unlikely to substantially reduce quality of life during the patient's lifetime.

Reduction of pretreatment IOP by ≥25% shown to slow progression of primary open-angle glaucoma. Set an initial target IOP (based on extent of optic nerve damage and/or visual field loss, baseline IOP at which damage occurred, rate of progression, life expectancy, and other considerations) and reduce IOP toward this goal. Adjust target IOP up or down as needed over course of disease.

Combination therapy with drugs from different therapeutic classes often required to control IOP.

Tafluprost Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the affected eye(s).

If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.

Use solution from one single-use container immediately after opening; immediately discard unused portion after administration.

Dosage